Covid-19 Research

Research Article

Novel Oncoplastic Surgery for Long-Term Outcome and Prediction of Breast Cancer Survival beyond Serial Axillary Dissection – A Prospective Study

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Medicine Group
OCLC JBRES Record
Mostaque AK*, Kamal M and Shariful Alam AMM
Issue: Volume7-Issue1
Pages: 1-17
Received: 2025-12-24
Accepted: 2026-01-18
Published: 2026-01-19

Abstract

Study background: Axillary Lymph Node Dissection (ALND) maintains therapeutic value in high-risk Breast Cancer (BC), while sentinel lymph node biopsy is the standard for staging early-stage, clinically node-negative cases to forecast prognosis. Skin sparing oncologic resection, breast lift and ipsilateral ALND of Oncoplastic Surgery (OPS) should cause proactive enlargement of cancer affected breast creating balanced symmetry. The objectives of study were (1) to observe the long-term outcomes of this ethically sound novel ALND-OPS model to evaluate efficacy and long-term outcome of this surgical technique, (2) to observe power of assessment of stratification and prognosis of pathological Node (pN) stages and Lymph Node Ratio (LNR) subgroups.
Methods: This single-center unique prospective cohort study was conducted on 51 consecutively treated BC patients. Three BC patients treated with novel ALND- OPS model were included where their long-term follow-up data were collected for analysis. The data collected of 51 cases were total and positive axillary node counts, patient distribution as per pN stages and Lymph Node Ratio (LNR) subgroups, and survival functions of Disease Free Survival (DFS) and Overall Survival (OS) at follow-up date focusing on the most severe cases where all patients eventually died to understand their full survival journey.
Results: Novel skin sparing ALND model OPS indicated recurrence-free, balanced, healthy, and symmetrical breasts after > 6 years follow-up. The median DFS and OS were 49.23 and 52.63 months respectively. Significant difference of patients stratification between pN and LNR subgroups (p = 0.000001) observed. Significant difference was observed of estimated mean survival time of DFS between low- and high-risk (p < 0.001), and intermediate- and high-risk LNR (p < 0.001), and of OS between low- and high-risk (p < 0.001), and intermediate- and high-risk LNR (p < 0.001) subgroups.
Conclusions: Ipsilateral axillary dissection model oncoplastic surgery is a novel ethically/surgically sound proactive procedure. Axillary dissection is a powerful independent predictor of breast cancer prognosis

FullText HTML FullText PDF DOI: 10.37871/jbres2256 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2026 Mostaque AK. et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Mostaque AK, Kamal M, Shariful Alam AMM. Novel Oncoplastic Surgery for Long-Term Outcome and Prediction of Breast Cancer Survival beyond Serial Axillary Dissection – A Prospective Study. J Biomed Res Environ Sci. 2026 Jan 19; 7(1): 17. Doi: 10.37871/jbres2256

Subject area(s)

Clinical TrialsOncologySurgery

References

  1. Freeman MD, Gopman JM, Salzberg CA. The evolution of mastectomy surgical technique: from mutilation to medicine. Gland Surg. 2018 Jun;7(3):308-315. doi: 10.21037/gs.2017.09.07. PMID: 29998080; PMCID: PMC6006018.
  2. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. PMID: 28898379; PMCID: PMC5672806.
  3. Mostaque AK, Mamun MAA, Kamal M, Alam AMMS, Chowdhury IU. Oncoplastic surgery and outcome prediction deserve axillary lymph node dissection – treatment results of 51 cases of breast cancer. IISJ. 2021.
  4. Arnone P, Zurrida S, Viale G, Dellapasqua S, Montagna E, Arnaboldi P, Intra M, Veronesi U. The TNM classification of breast cancer: need for change. Updates Surg. 2010 Oct;62(2):75-81. doi: 10.1007/s13304-010-0014-y. PMID: 20845013.
  5. Sawaki M, Shien T, Iwata H. TNM classification of malignant tumors (Breast Cancer Study Group). Jpn J Clin Oncol. 2019 Mar 1;49(3):228-231. doi: 10.1093/jjco/hyy182. PMID: 30541035.
  6. Xiao XS, Tang HL, Xie XH, Li LS, Kong YN, Wu MQ, Yang L, Gao J, Wei WD, Xie X. Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution. Asian Pac J Cancer Prev. 2013;14(9):5219-23. doi: 10.7314/apjcp.2013.14.9.5219. PMID: 24175804.
  7. Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary Nodal Evaluation in Breast Cancer: State of the Art. Radiology. 2020 Jun;295(3):500-515. doi: 10.1148/radiol.2020192534. Epub 2020 Apr 21. PMID: 32315268.
  8. Safavi A, Kaviani A, Mohammadzadeh N, Zand S, Krag DN. Breast cancer prognostication by pathologic node staging (pN-staging) system versus Lymph Node Ratio (LNR): A critical review of conflicts with number of nodes, Z-0011 trial, staging cut- points, neo-adjuvant therapy and survival estimation. Arch Breast Cancer. 2017 Nov;4(4):110-123. doi: 10.19187/abc.201744110-123.
  9. Zhao X, Wei J, Li X, Yang H, Wang P, Cao S. Increasing negative lymph node count predicts favorable OS and DSS in breast cancer with different lymph node-positive subgroups. PLoS One. 2018 Mar 19;13(3):e0193784. doi: 10.1371/journal.pone.0193784. PMID: 29554092; PMCID: PMC5858777.
  10. Koh J, Kim MJ. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. Korean J Radiol. 2019 Jan;20(1):69-82. doi: 10.3348/kjr.2018.0231. Epub 2018 Dec 27. Erratum in: Korean J Radiol. 2022 May;23(5):570. doi: 10.3348/kjr.2022.0246. PMID: 30627023; PMCID: PMC6315072.
  11. Mostaque AK, Mamun MAA, Alam AMMS, Chowdhury IU, Sharif RB. Assessment of anthropometric measurements, time lag between diagnosis and surgery, postoperative recovery time, and outcome of oncoplastic surgery of treated breast cancer patients. J MAR Oncol. 2022.
  12. Thompson PW, Chatterge A, Losken A. Standards in oncoplastic breast-conserving surgery. Ann Breast Surg. 2021;6:37. doi: 10.21037/abs-21-33.
  13. Kar A, Ray S, Behera PK, Mohanty L, Das PK, Biswal P. Evaluation of lymph node ratios and log odds of positive nodes as prognostic indicators in primary organ malignancy. Med J Armed Forces India. 2025 Jul;81(Suppl 1):S126-S134. doi: 10.1016/j.mjafi.2024.08.012. Epub 2024 Oct 18. PMID: 40822071; PMCID: PMC12351035.
  14. Wu SG, He ZY, Li Q, Sun JY, Li FY, Lin Q, Lin HX, Guan XX. Prognostic value of metastatic axillary lymph node ratio for Chinese breast cancer patients. PLoS One. 2013 Apr 23;8(4):e61410. doi: 10.1371/journal.pone.0061410. PMID: 23626682; PMCID: PMC3634079.
  15. Liu J, Li Y, Zhang W, Yang C, Yang C, Chen L, Ding M, Zhang L, Liu X, Cui G, Liu Y. The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis. Front Surg. 2022 Oct 26;9:971030. doi: 10.3389/fsurg.2022.971030. PMID: 36386510; PMCID: PMC9644128.
  16. Campanale A, Ventimiglia M, Alfò M, Cipriani M, Minella D, Lispi L, Iachino A. Current Knowledge on Breast Implant-Associated Anaplastic Large Cell Lymphoma: Evidence from Italian Ministry of Health Registry Data. Aesthetic Plast Surg. 2025 Mar;49(5):1304-1313. doi: 10.1007/s00266-024-04426-y. Epub 2024 Oct 14. PMID: 39402199.
  17. Trieu PDY, Mello-Thoms CR, Barron ML, Lewis SJ. Look how far we have come: BREAST cancer detection education on the international stage. Front Oncol. 2023 Jan 4;12:1023714. doi: 10.3389/fonc.2022.1023714. PMID: 36686760; PMCID: PMC9846523.
  18. Gou Z, Lu X, He M, Yu L. Trends in axillary surgery and clinical outcomes among breast cancer patients with sentinel node metastasis. Breast. 2022 Jun;63:9-15. doi: 10.1016/j.breast.2022.02.014. Epub 2022 Mar 1. PMID: 35245747; PMCID: PMC8892150.
  19. García-Novoa A, Acea-Nebril B, Casal-Beloy I, Bouzón-Alejandro A, Cereijo Garea C, Gómez-Dovigo A, Builes-Ramírez S, Santiago P, Mosquera-Oses J. The decline of axillary lymph node dissection in breast cancer. Evolution of its indication over the last 20 years. Cir Esp (Engl Ed). 2019 Apr;97(4):222-229. English, Spanish. doi: 10.1016/j.ciresp.2019.01.010. Epub 2019 Mar 8. PMID: 30857734.
  20. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005 Oct 1;23(28):7114-24. doi: 10.1200/JCO.2005.14.621. PMID: 16192595.
  21. Soran A, Ozmen T, Salamat A, Soybir G, Johnson R. Lymph Node Ratio (LNR): Predicting Prognosis after Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients. Eur J Breast Health. 2019 Oct 1;15(4):249-255. doi: 10.5152/ejbh.2019.4848. PMID: 31620684; PMCID: PMC6776131.
  22. Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database. PLoS One. 2016 Oct 31;11(10):e0165409. doi: 10.1371/journal.pone.0165409. PMID: 27798652; PMCID: PMC5087840.
  23. Tonellotto F, Bergmann A, de Souza Abrahão K, de Aguiar SS, Bello MA, Thuler LCS. Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. Eur J Breast Health. 2019 Apr 1;15(2):76-84. doi: 10.5152/ejbh.2019.4414. PMID: 31001608; PMCID: PMC6456272.
  24. Xie Y, Deng Y, Wei S, Huang Z, Li L, Huang K, Wei C, Xu J, Dong L, Zhang Q, Zhao J, Zou Q, Yang J. Age has a U-shaped relationship with breast cancer outcomes in women: a cohort study. Front Oncol. 2023 Oct 4;13:1265304. doi: 10.3389/fonc.2023.1265304. PMID: 37860197; PMCID: PMC10583555.
  25. Zangouri V, Balaneji SS, Golmoradi R, Kafili E, Bologhi S, Mousavi SA, Hesar AA, Amestejani M. Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer. BMC Cancer. 2025 Feb 13;25(1):257. doi: 10.1186/s12885-025-13638-7. PMID: 39948483; PMCID: PMC11827321.
  26. Liu Y, He M, Zuo WJ, Hao S, Wang ZH, Shao ZM. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. Front Oncol. 2021 Apr 9;11:585613. doi: 10.3389/fonc.2021.585613. PMID: 33898305; PMCID: PMC8064390.
  27. Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundag K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON. 2015 May-Jun;20(3):737-45. PMID: 26214625.
  28. Gentile D, Sagona A, De Carlo C, Fernandes B, Barbieri E, Di Maria Grimaldi S, Jacobs F, Vatteroni G, Scardina L, Biondi E, Vinci V, Trimboli RM, Bernardi D, Tinterri C. Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients. Breast. 2023 Jun;69:323-329. doi: 10.1016/j.breast.2023.03.016. Epub 2023 Mar 28. PMID: 37001289; PMCID: PMC10070173.
  29. Sbaity E, Tamim H, El-Hajj Fuleihan G, Abbas J, Zahwe M, El Sayed R, Shamseddine A. Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study. BMC Cancer. 2024 May 4;24(1):560. doi: 10.1186/s12885-024-11910-w. PMID: 38704543; PMCID: PMC11069273.
  30. Löb S, Linsmeier E, Herbert SL, Schlaiß T, Kiesel M, Wischhusen J, Salmen J, Kranke P, Quenzer A, Kurz F, Weiss C, Gerhard-Hartmann E, Wöckel A, Diessner J. Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases. J Cancer Res Clin Oncol. 2023 Jul;149(8):5417-5428. doi: 10.1007/s00432-022-04486-0. Epub 2022 Dec 1. PMID: 36451043; PMCID: PMC10349762.
  31. Li CY, Kataru RP, Mehrara BJ. Histopathologic Features of Lymphedema: A Molecular Review. Int J Mol Sci. 2020 Apr 6;21(7):2546. doi: 10.3390/ijms21072546. PMID: 32268536; PMCID: PMC7177532.
  32. Donahue PM, Crescenzi R, Scott AO, Braxton V, Desai A, Smith SA, Jordi J, Meszoely IM, Grau AM, Kauffmann RM, Sweeting RS, Spotanski K, Ridner SH, Donahue MJ. Bilateral Changes in Deep Tissue Environment After Manual Lymphatic Drainage in Patients with Breast Cancer Treatment-Related Lymphedema. Lymphat Res Biol. 2017 Mar;15(1):45-56. doi: 10.1089/lrb.2016.0020. PMID: 28323572; PMCID: PMC5369395.
  33. Rauner G, Jin DX, Miller DH, Gierahn TM, Li CM, Sokol ES, Feng YX, Mathis RA, Love JC, Gupta PB, Kuperwasser C. Breast tissue regeneration is driven by cell-matrix interactions coordinating multi-lineage stem cell differentiation through DDR1. Nat Commun. 2021 Dec 10;12(1):7116. doi: 10.1038/s41467-021-27401-6. PMID: 34893587; PMCID: PMC8664951.
  34. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Cataliotti L, Westenberg AH, Klinkenbijl JHG, Orzalesi L, Bouma WH, Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, Slaets L, Duez N, Graaf PW, Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Messina CGM, Bogaerts J, Rutgers EJT. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017 Nov;318(10):918-926. doi: 10.1001/jaa.2017.11470 PMID: 25439688 PMCID: PMC4291166
  35. Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565. Epub 2022 Nov 16. PMID: 36383926.
  36. de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. PMID: 38598571.
  37. Lim GH, Al Shukairi AM, Lee YS, Teo SY, Yan Z, Tan QT, Gudi M, Ng RP, Wong FY. Targeted axillary dissection in breast cancer patients with metastatic nodal disease: a prospective study on localization techniques and oncological outcomes. Gland Surg. 2025 Aug 31;14(8):1529-1538. doi: 10.21037/gs-2025-166. Epub 2025 Aug 20. PMID: 40948928; PMCID: PMC12432960.
  38. Tayade MC, Dalvi SD. Fundamental Ethical Issues in Unnecessary Surgical Procedures. J Clin Diagn Res. 2016 Apr;10(4):JE01-4. doi: 10.7860/JCDR/2016/18958.7694. Epub 2016 Apr 1. PMID: 27190833; PMCID: PMC4866131.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership